»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ Ui?t@.
t`F%$q
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 ss,6;wfX
zEks4yd
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© -sc@SoS
1.Antigen presenting cell£¨APC£© Nb B`6@r
2.Activation induced cell death£¨AICD£© {BKI8vy
3.Chemokine :+[q
`
4.Major histocompatibility complex£¨MHC£© E; RI.6y
5.immunotolerance "]JS,g {m
(_-zm)F7
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© 8.9S91]=
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ xY_/CR[,
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà kyY tL_SD
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ IClnh1=
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ lT$A;7[
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã /u#uC(Uwl
fmloh1{4
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© n{U
B^-}5
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ *4r;H2%c
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ BQw#PXp3
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ eOLS
r[~Km5
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ D+"5R5J",
O{%y `|m
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 jQ7RH/?_
v
?Y9z!M
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ [g<6i.<I
1.Antigenic determinant vw+
@'+
2.IgSF j7uiZU;3Rx
3.MBL;¾¶ c
t,p?[Q
4.chemokine YFs
EuaV
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ )!M:=}."
6.TCR-CD3¸´ºÏÎï )e{~x
u
7.FADD£¨Fas-associated protein with death domain£© Vh'H5v^
8.AIDS X"'}1o
9.Tumor rejection antigen #msk'MVt
10.AICD mJWl#3
I_eYTy-a`1
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ })ss.
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© S{J$[!F
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ Az"3f
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ [}d
3u!
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì /t
,ujTK
v#D9yttO{
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ ZYkeW
j1<@*W&b
xae}8E
רҵ¿Î ÃâÒßѧ v,1.n{!;
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê {P-KU RQ
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell _.wLQL~y
5. Fc¦Å receptor 6. Cytokine &*L:4By)]
¶þ¡¢ ÎÊ´ðÌâ cdzMao
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 ZK_
IK)g
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ vZ$uD,@;.
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ I@ }:} 8t
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 {"'W!WTb
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠH9nZ%n
b)'Ew27
WynH
cxC
-\AB!#fh
(!{_O_&
z`5+BL,|ND
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ g:e|
~"brfjd|
>0:h(,?V
רҵ¿Î ÃâÒßѧ &l{yEWA}g
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê "t`r_Aw
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen y|iZuHS}
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin p !U#53
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test y.w/7iw:
9. Hybridoma technic 10.Mitogen a5z.c_7r
11.Dentritic cell 12.Immunoproliferation Z
dj~B1
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ 44RZk|U1J{
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ m->
chOu~|
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠ#=Q/<r.~G
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ JB''Ujyi
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ fC]+C(*d
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ ZEUd?"gaR
%!p14c*J H
6SlE>b9tA
B;hc|v{(
76$19
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 1\kOjF)l
k$k(g
<74q]C
רҵ¿Î ÃâÒßѧ k;;?3)!
Ò»¡¢ Ãû´Ê½âÊÍ o9q%=/@,
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï ;QREwT~H
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà QVn!60[lj
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ {B?%r[nW
¶þ¡¢ ÎÊ´ðÌâ 7+#^:;19`
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ Y?ZTl762
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£
m5{Y
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ V*U"OJ%
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ #}:VZ2Z
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ [$8*(d"F'
zP
rT0
ZV_mP'1*
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 2s?j5 Sd
\
$X3n\
s3/->1#i
רҵ¿Î ÃâÒßѧ UyD=x(li
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê b;9v.MZ4>g
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR a%Mbq;
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA _Dwn@{[(8
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM \dbpCZ
¶þ¡¢ ÎÊ´ðÌâ +qD4`aI
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ K
,f 1c}
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ jR}h3!
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ D@>P%k$$s>
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ >pG]#Z g
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ K&D
-1u
%}+j4n
Uc<B)7{'
TnPd pynP
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ }\*dD2qNL}
7:mM`0g!
xyBe*,u
רҵ¿Î ÃâÒßѧ JQQD~J1)E
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 2X]2;W)S;
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule /<zBcpVNV
5. Autogous mixed lymphoyte reaction YpL{c* M
¶þ¡¢ ÎÊ´ðÌâ H.O7Y
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ 76zi)f1f
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ Pt";f
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷ÓᣠV8[woJ5x
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿
UZmzk
w/h?, L|
9t7_7{Q+;
-[0)n{AVvU
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ :Oa|&.0l?
gPQ2i])"Q
S[X bb=n
רҵ¿Î ÃâÒßѧ $LF zpg
0qw,R4YK
A;Xn#t ,(K
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 2[
qO;js
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance {j ${i
5. Delayed type hypersensitivity G/N'8Q)
¶þ¡¢ ÎÊ´ðÌâ J3S@1"
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ 42ttmN1F
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ }yx'U 3
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ ;IXDZ#;
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ#f\U3p
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷Óᣠ\96?OCdr
My,ki:V?g6
psgXJe$
9~
K1+%!
o*'J8El\y^
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ a}hpcr({?
j:O=9
2\CFt;fk
רҵ¿Î ÃâÒßѧ 8`U5/!6fu
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 1EyM,$On
1. hypersensitivity 2. cluster of differentiation 4g$mz
:vo
3. adhesion molecules 4. supper antigen 5. split tolerance )0yY|E
\
¶þ¡¢ ÎÊ´ðÌâ RUlM""@b
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ M_Z*F!al<
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ H}dsd=yO
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ z,X
^;
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ UyEyk$6SU
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ " <m)Fh;
R1&(VK{
O-U_Zx0zd
M})2y+
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ O<)"kj 7
רҵ¿Î ÃâÒßѧ !FA^~
Ò»¡¢ Ãû´Ê½âÊÍ [8^jwnAYS
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å X%h1r`h&
5. GVHR u;F++$=
¶þ¡¢ ÎÊ´ðÌâ 4IG'Tm
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷Óᣠ;Tvy)*{
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌØµãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ J&@[=zBYw
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌØµã¡£ T]Vh]|_s
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ f]h99T
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ k10dkBoEX
lw\OsB$
"o*F$7D!
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ sG%Q?&-
C8
m8ys
E@}t1!E<
רҵ¿Î ÃâÒßѧ #6 e
Ò»¡¢Ãû´Ê½âÊÍ Gm}ecW
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å ;4z6="<Y
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ `$JPF Z
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ &y;('w
11. »ìºÏÁܰÍϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ t9Ht
54
Èý¡¢ ÎÊ´ðÌâ
)Jz L
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ +Tf ,2?O
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ ~]*P/'-{#
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà 1 xm8w$%
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ )V*Z|,#no
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ 6wYd)MDLL
V2W)%c'
<{Wsh#7 }.
f]tc$`vb
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ V*@pmOhz
>)YaWcI
y
Rr,+>W
רҵ¿Î ÃâÒßѧ _Y4%Fv>@
Ò»¡¢Ãû´Ê½âÊÍ +/'3=!oyd
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó 6J9^:gXW~
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁܰÍϸ°ûµÄ±íÃæ±êÖ¾ ng(STvSh:
Èý¡¢ ÎÊ´ðÌâ D4g
$x'
1. ¼òÊöTÁܰÍϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ ?B.>VnYZ/a
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ rK;F]ei
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ R#eY@N}\
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ 81u}J9z;
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ ;HtHN
K(o
%e.tAl"!$
`bw>.Ay
'!>LF1W=
PTfTT_t
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ J8
>y2rAi
Ò»¡¢Ãû´Ê½âÊÍ X-%XZDB6
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï d%FD=wm
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó tu8n1
W
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ uH7$/
¶þ¡¢ ÎÊ´ðÌâ ~UA:_7#\M
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ `1aEV#;
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ ^}vL ZA
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ kXK D>."E*
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ *Y8nea^$
wN'Q\l+
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ @(Q'J`
Ò»¡¢ Ãû´Ê½âÊÍ 3m:[o`L
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ w9h`8pt
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ (`<X9w,
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© C{AVV<
10¡¢ ÒõÐÔÑ¡Ôñ d;1%Ei3K
¶þ¡¢ ÎÊ´ðÌâ <d!_.f}v
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 }j9V0`Q
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ VA{2a7]
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 Z<+Ip
j&
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ %6c[\ubr
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. `j+[JMr
IjJO;
R)4L]Z
F
_4H
9rPhf
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ U8Rko)
rZ}y'A
%^1@c f?.
רҵ¿Î ÃâÒßѧ n
*Y+y
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ 3!]S8Y*LQP
1. Cytokines 2. adhesion molecules 3. graft versus host reaction #{97<sU\
4. immunologic tolerance 5. Opsonization H$GJpXIb
Èý¡¢ ÎÊ´ðÌâ R Ptc \
4
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷ÓᣠwCT. (d_
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ ="X2AuK%1$
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ 9em?2'ysa
4. ÃâÒßϵͳɱÉ˰Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ ks{y=@<,
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ !8'mIXZ$
ue?e}hF
JQSp2b@'H
Ih_2")d
mRJX,
jV:Krk6T<
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ CVo2?ZQ
T4H/D^X|
O+ ].'
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ fC1PPgQ\
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ o u%Xnk~
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê RZKdh
}B?\
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ 1^F
!X=
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û cu)ssT
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö '!$g<= @
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð a!OS2Tz:
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖÆ±¸ÔÀí¡£ a?63 5*9K
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ >j&+mii
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃæ¿¹ÔºÍ±íÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© m6'VM
W
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ '*`25BiQ
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ jY: )W*TXt
rt5FecX\
-> $]`h"
"4`i]vy8
uv&??F]/
Q~p)@[q
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ UG@9X/l}
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ H>zX8qP+
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ nTy8:k ']
mgODJ
Ò»¡¢ Ãû´Ê½âÊÍ ^`BiA'gPPC
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß wW.V>$q
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò mNc?`G_R
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô t[dOWgHi
¶þ¡¢ÎÊ´ðÌâ o7_*#5rD
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ n5Coxvy1
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì \3WF-!xe
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì <./r%3$;7
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ %a'Nf/9=:
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ }fS`jq;
w<qn @f